Raras
Buscar doenças, sintomas, genes...
Síndrome distonia-plus
ORPHA:98203PCDT · SUSDOENÇA RARA

Distonia combinada com outro distúrbio do movimento (por exemplo, mioclonia, parkinsonismo).

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Distonia combinada com outro distúrbio do movimento (por exemplo, mioclonia, parkinsonismo).

Pesquisas ativas
1 ensaio
1 total registrados no ClinicalTrials.gov
Publicações científicas
54 artigos
Último publicado: 2026 Apr 13
Medicamentos
1 registrados
ZONISAMIDE

Tem tratamento?

1 medicamento registrado
Ver detalhes, fases e interações →
ZONISAMIDE
🏥
SUS: Cobertura mínimaScore: 30%
PCDT disponível
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧠
Neurológico
42 sintomas
💪
Músculos
19 sintomas
🫃
Digestivo
5 sintomas
🫘
Rins
5 sintomas
📏
Crescimento
4 sintomas
🫁
Pulmão
3 sintomas

+ 91 sintomas em outras categorias

Características mais comuns

Movimentos hipercinesia
Concentração diminuída de ácido homovanílico no LCR
Distonia do braço
Traço obsessivo-compulsivo
Aumento da serotonina sérica
Distonia da perna
181sintomas
Sem dados (181)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 181 características clínicas mais associadas, ordenadas por frequência.

Movimentos hipercinesiaHyperkinetic movements
Concentração diminuída de ácido homovanílico no LCRDecreased CSF homovanillic acid concentration
Distonia do braçoArm dystonia
Traço obsessivo-compulsivoObsessive-compulsive trait
Aumento da serotonina séricaIncreased serum serotonin

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico54PubMed
Últimos 10 anos48publicações
Pico20218 papers
Linha do tempo
2026Hoje · 2026🧪 2001Primeiro ensaio clínico📈 2021Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

19 genes identificados com associação a esta condição.

SLC18A2Synaptic vesicular amine transporterDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Electrogenic antiporter that exchanges one cationic monoamine with two intravesicular protons across the membrane of secretory and synaptic vesicles. Uses the electrochemical proton gradient established by the V-type proton-pump ATPase to accumulate high concentrations of monoamines inside the vesicles prior to their release via exocytosis. Transports a variety of catecholamines such as dopamine, adrenaline and noradrenaline, histamine, and indolamines such as serotonin (PubMed:23363473, PubMed:

LOCALIZAÇÃO

Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membraneCytoplasmic vesicle, secretory vesicle membraneCell projection, axonCell projection, dendrite

VIAS BIOLÓGICAS (3)
Serotonin Neurotransmitter Release CycleDopamine Neurotransmitter Release CycleNorepinephrine Neurotransmitter Release Cycle
MECANISMO DE DOENÇA

Parkinsonism-dystonia 2, infantile-onset

An autosomal recessive disorder characterized by infantile onset of abnormal movements, including parkinsonism, dystonia, and poor fine motor skills, as well as autonomic dysfunction, including abnormal sweating, cold extremities, and poor sleep. Some patients have variable degrees of developmental delay.

EXPRESSÃO TECIDUAL(Tecido-específico)
Vagina
8.0 TPM
Ovário
6.9 TPM
Cervix Endocervix
6.0 TPM
Cervix Ectocervix
5.9 TPM
Pulmão
5.4 TPM
OUTRAS DOENÇAS (1)
brain dopamine-serotonin vesicular transport disease
HGNC:10935UniProt:Q05940
ATMSerine-protein kinase ATMCandidate gene tested inTolerante
FUNÇÃO

Serine/threonine protein kinase which activates checkpoint signaling upon double strand breaks (DSBs), apoptosis and genotoxic stresses such as ionizing ultraviolet A light (UVA), thereby acting as a DNA damage sensor (PubMed:10550055, PubMed:10839545, PubMed:10910365, PubMed:12556884, PubMed:14871926, PubMed:15064416, PubMed:15448695, PubMed:15456891, PubMed:15790808, PubMed:15916964, PubMed:17923702, PubMed:21757780, PubMed:24534091, PubMed:35076389, PubMed:9733514). Recognizes the substrate c

LOCALIZAÇÃO

NucleusCytoplasmic vesicleCytoplasm, cytoskeleton, microtubule organizing center, centrosomePeroxisome matrix

VIAS BIOLÓGICAS (5)
DNA Damage/Telomere Stress Induced SenescenceSensing of DNA Double Strand BreaksTP53 Regulates Transcription of DNA Repair GenesMeiotic recombinationRegulation of HSF1-mediated heat shock response
MECANISMO DE DOENÇA

Ataxia telangiectasia

A rare recessive disorder characterized by progressive cerebellar ataxia, dilation of the blood vessels in the conjunctiva and eyeballs, immunodeficiency, growth retardation and sexual immaturity. Patients have a strong predisposition to cancer; about 30% of patients develop tumors, particularly lymphomas and leukemias. Cells from affected individuals are highly sensitive to damage by ionizing radiation and resistant to inhibition of DNA synthesis following irradiation.

OUTRAS DOENÇAS (9)
ataxia telangiectasiaATM-related cancer predispositionfamilial colorectal cancer type XB-cell chronic lymphocytic leukemia
HGNC:795UniProt:Q13315
CACNA1AVoltage-dependent P/Q-type calcium channel subunit alpha-1ACandidate gene tested inAltamente restrito
FUNÇÃO

Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1A gives rise to P and/or Q-type calcium currents. P/Q-type calcium channels belong to the 'high-voltage activated' (HVA) group and are specifically blocked by the spider omega-agatoxin-IVA

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (2)
Presynaptic depolarization and calcium channel openingRegulation of insulin secretion
MECANISMO DE DOENÇA

Spinocerebellar ataxia 6

Spinocerebellar ataxia is a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCA6 is an autosomal dominant cerebellar ataxia (ADCA), mainly caused by expansion of a CAG repeat in the coding region of CACNA1A. There seems to be a correlation between the repeat number and earlier onset of the disorder.

OUTRAS DOENÇAS (9)
migraine, familial hemiplegic, 1episodic ataxia type 2developmental and epileptic encephalopathy, 42spinocerebellar ataxia type 6
HGNC:1388UniProt:O00555
KCNJ10ATP-sensitive inward rectifier potassium channel 10Candidate gene tested inModerado
FUNÇÃO

May be responsible for potassium buffering action of glial cells in the brain (By similarity). Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it (PubMed:8995301). Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages (PubMed:8995301). The inward rectification is mainly d

LOCALIZAÇÃO

MembraneBasolateral cell membrane

VIAS BIOLÓGICAS (3)
Activation of G protein gated Potassium channelsInhibition of voltage gated Ca2+ channels via Gbeta/gamma subunitsPotassium transport channels
MECANISMO DE DOENÇA

Seizures, sensorineural deafness, ataxia, impaired intellectual development, and electrolyte imbalance

A complex disorder characterized by generalized seizures with onset in infancy, delayed psychomotor development, ataxia, sensorineural hearing loss, hypokalemia, metabolic alkalosis, and hypomagnesemia.

EXPRESSÃO TECIDUAL(Tecido-específico)
Brain Spinal cord cervical c-1
132.0 TPM
Brain Caudate basal ganglia
61.6 TPM
Substância negra
60.1 TPM
Brain Putamen basal ganglia
56.0 TPM
Córtex cerebral
49.6 TPM
OUTRAS DOENÇAS (4)
autosomal recessive nonsyndromic hearing loss 4EAST syndromePendred syndromeepisodic kinesigenic dyskinesia
HGNC:6256UniProt:P78508
KCNA1Potassium voltage-gated channel subfamily A member 1Candidate gene tested inTolerante
FUNÇÃO

Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain and the central nervous system, but also in the kidney (PubMed:19903818, PubMed:8845167). Contributes to the regulation of the membrane potential and nerve signaling, and prevents neuronal hyperexcitability (PubMed:17156368). Forms tetrameric potassium-selective channels through which potassium ions pass in accordance with their electrochemical gradient. The channel alte

LOCALIZAÇÃO

Cell membraneMembraneCell projection, axonCytoplasmic vesiclePerikaryonEndoplasmic reticulumCell projection, dendriteCell junctionSynapsePresynaptic cell membranePresynapse

VIAS BIOLÓGICAS (1)
Voltage gated Potassium channels
MECANISMO DE DOENÇA

Episodic ataxia 1

An autosomal dominant disorder characterized by brief episodes of ataxia and dysarthria. Neurological examination during and between the attacks demonstrates spontaneous, repetitive discharges in the distal musculature (myokymia) that arise from peripheral nerve. Nystagmus is absent.

EXPRESSÃO TECIDUAL(Tecido-específico)
Cérebro - Hemisfério cerebelar
56.0 TPM
Cerebelo
42.4 TPM
Brain Frontal Cortex BA9
13.3 TPM
Brain Nucleus accumbens basal ganglia
7.8 TPM
Brain Caudate basal ganglia
7.8 TPM
OUTRAS DOENÇAS (5)
episodic ataxia type 1early-infantile DEEepisodic kinesigenic dyskinesiahereditary continuous muscle fiber activity
HGNC:6218UniProt:Q09470
DRD2D(2) dopamine receptorCandidate gene tested inAltamente restrito
FUNÇÃO

Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase (PubMed:21645528). Positively regulates postnatal regression of retinal hyaloid vessels via suppression of VEGFR2/KDR activity, downstream of OPN5 (By similarity)

LOCALIZAÇÃO

Cell membraneGolgi apparatus membrane

VIAS BIOLÓGICAS (1)
Dopamine receptors
VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Tecido-específico)
Pituitária
81.4 TPM
Brain Nucleus accumbens basal ganglia
51.9 TPM
Brain Putamen basal ganglia
45.7 TPM
Brain Caudate basal ganglia
40.7 TPM
Glândula salivar
11.4 TPM
OUTRAS DOENÇAS (1)
myoclonus-dystonia syndrome
HGNC:3023UniProt:P14416
TOR1ATorsin-1ACandidate gene tested inTolerante
FUNÇÃO

Protein with chaperone functions important for the control of protein folding, processing, stability and localization as well as for the reduction of misfolded protein aggregates. Involved in the regulation of synaptic vesicle recycling, controls STON2 protein stability in collaboration with the COP9 signalosome complex (CSN). In the nucleus, may link the cytoskeleton with the nuclear envelope, this mechanism seems to be crucial for the control of nuclear polarity, cell movement and, specificall

LOCALIZAÇÃO

Endoplasmic reticulum lumenNucleus membraneCell projection, growth coneCytoplasmic vesicle membraneCytoplasmic vesicle, secretory vesicleCytoplasmic vesicle, secretory vesicle, synaptic vesicleCytoplasm, cytoskeleton

VIAS BIOLÓGICAS (1)
Cargo recognition for clathrin-mediated endocytosis
MECANISMO DE DOENÇA

Dystonia 1, torsion, autosomal dominant

A primary torsion dystonia, and the most common and severe form. Dystonia is defined by the presence of sustained involuntary muscle contractions, often leading to abnormal postures. Dystonia type 1 is characterized by involuntary, repetitive, sustained muscle contractions or postures involving one or more sites of the body, in the absence of other neurological symptoms. Typically, symptoms develop first in an arm or leg in middle to late childhood and progress in approximately 30% of patients to other body regions (generalized dystonia) within about five years. 'Torsion' refers to the twisting nature of body movements observed in DYT1, often affecting the trunk. Distribution and severity of symptoms vary widely between affected individuals, ranging from mild focal dystonia to severe generalized dystonia, even within families.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
47.1 TPM
Útero
27.4 TPM
Aorta
26.7 TPM
Linfócitos
26.6 TPM
Artéria tibial
25.9 TPM
OUTRAS DOENÇAS (3)
early-onset generalized limb-onset dystoniaarthrogryposis multiplex congenita 5myoclonus-dystonia syndrome
HGNC:3098UniProt:O14656
ARXHomeobox protein ARXCandidate gene tested inAltamente restrito
FUNÇÃO

Transcription factor (PubMed:22194193, PubMed:31691806). Binds to specific sequence motif 5'-TAATTA-3' in regulatory elements of target genes, such as histone demethylase KDM5C (PubMed:22194193, PubMed:31691806). Positively modulates transcription of KDM5C (PubMed:31691806). Activates expression of KDM5C synergistically with histone lysine demethylase PHF8 and perhaps in competition with transcription regulator ZNF711; synergy may be related to enrichment of histone H3K4me3 in regulatory element

LOCALIZAÇÃO

Nucleus

MECANISMO DE DOENÇA

Lissencephaly, X-linked 2

A classic type lissencephaly associated with abnormal genitalia. Patients have severe congenital or postnatal microcephaly, lissencephaly, agenesis of the corpus callosum, neonatal-onset intractable epilepsy, poor temperature regulation, chronic diarrhea, and ambiguous or underdeveloped genitalia.

OUTRAS DOENÇAS (9)
X-linked lissencephaly with abnormal genitaliaPartington syndromecorpus callosum agenesis-abnormal genitalia syndromedevelopmental and epileptic encephalopathy, 1
HGNC:18060UniProt:Q96QS3
TAF1Transcription initiation factor TFIID subunit 1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

The TFIID basal transcription factor complex plays a major role in the initiation of RNA polymerase II (Pol II)-dependent transcription (PubMed:33795473). TFIID recognizes and binds promoters with or without a TATA box via its subunit TBP, a TATA-box-binding protein, and promotes assembly of the pre-initiation complex (PIC) (PubMed:33795473). The TFIID complex consists of TBP and TBP-associated factors (TAFs), including TAF1, TAF2, TAF3, TAF4, TAF5, TAF6, TAF7, TAF8, TAF9, TAF10, TAF11, TAF12 an

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (9)
Regulation of TP53 Activity through PhosphorylationRNA Polymerase II Promoter EscapeRNA Polymerase II HIV Promoter EscapeRNA Polymerase II Pre-transcription EventsHIV Transcription Initiation
MECANISMO DE DOENÇA

Dystonia 3, torsion, X-linked

An X-linked dystonia-parkinsonism disorder. Dystonia is defined by the presence of sustained involuntary muscle contractions, often leading to abnormal postures. DYT3 is characterized by severe progressive torsion dystonia followed by parkinsonism. It has a well-defined pathology of extensive neuronal loss and mosaic gliosis in the striatum (caudate nucleus and putamen) which appears to resemble that in Huntington disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Útero
26.5 TPM
Cervix Endocervix
26.3 TPM
Ovário
25.0 TPM
Cervix Ectocervix
23.9 TPM
Fallopian Tube
23.4 TPM
OUTRAS DOENÇAS (2)
intellectual disability, X-linked, syndromic 33X-linked dystonia-parkinsonism
HGNC:11535UniProt:P21675
ATP1A3Sodium/potassium-transporting ATPase subunit alpha-3Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates the electrochemical gradient of sodium and potassium ions, providing the energy for active transport of various nutrients

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (3)
Ion homeostasisIon transport by P-type ATPasesPotential therapeutics for SARS
MECANISMO DE DOENÇA

Dystonia 12

An autosomal dominant dystonia-parkinsonism disorder. Dystonia is defined by the presence of sustained involuntary muscle contractions, often leading to abnormal postures. DYT12 patients develop dystonia and parkinsonism between 15 and 45 years of age. The disease is characterized by an unusually rapid evolution of signs and symptoms. The sudden onset of symptoms over hours to a few weeks, often associated with physical or emotional stress, suggests a trigger initiating a nervous system insult resulting in permanent neurologic disability.

OUTRAS DOENÇAS (6)
developmental and epileptic encephalopathy 99cerebellar ataxia-areflexia-pes cavus-optic atrophy-sensorineural hearing loss syndromedystonia 12alternating hemiplegia of childhood 2
HGNC:801UniProt:P13637
PRRT2Proline-rich transmembrane protein 2Disease-causing germline mutation(s) inRestrito
FUNÇÃO

As a component of the outer core of AMPAR complex, may be involved in synaptic transmission in the central nervous system. In hippocampal neurons, in presynaptic terminals, plays an important role in the final steps of neurotransmitter release, possibly by regulating Ca(2+)-sensing. In the cerebellum, may inhibit SNARE complex formation and down-regulate short-term facilitation

LOCALIZAÇÃO

Cell membranePresynaptic cell membraneSynapseCell projection, axonCytoplasmic vesicle, secretory vesicle, synaptic vesicle membranePostsynaptic density membraneCell projection, dendritic spine

MECANISMO DE DOENÇA

Episodic kinesigenic dyskinesia 1

An autosomal dominant form of paroxysmal kinesigenic dyskinesia, a neurologic condition characterized by recurrent and brief attacks of abnormal involuntary movements, triggered by sudden voluntary movement. These attacks usually have onset during childhood or early adulthood and can involve dystonic postures, chorea, or athetosis.

EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
606.4 TPM
Cérebro - Hemisfério cerebelar
563.4 TPM
Ovário
183.2 TPM
Brain Frontal Cortex BA9
167.2 TPM
Córtex cerebral
152.5 TPM
OUTRAS DOENÇAS (9)
episodic kinesigenic dyskinesia 1seizures, benign familial infantile, 2infantile convulsions and choreoathetosisfamilial or sporadic hemiplegic migraine
HGNC:30500UniProt:Q7Z6L0
WARS2Tryptophan--tRNA ligase, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the attachment of tryptophan to tRNA(Trp) in a two-step reaction: tryptophan is first activated by ATP to form Trp-AMP and then transferred to the acceptor end of tRNA(Trp)

LOCALIZAÇÃO

Mitochondrion matrixMitochondrion

VIAS BIOLÓGICAS (1)
Mitochondrial tRNA aminoacylation
MECANISMO DE DOENÇA

Neurodevelopmental disorder, mitochondrial, with abnormal movements and lactic acidosis, with or without seizures

An autosomal recessive, mitochondrial disorder with a broad phenotypic spectrum ranging from severe neonatal lactic acidosis, encephalomyopathy and early death to an attenuated course with milder manifestations. Clinical features include delayed psychomotor development, intellectual disability, hypotonia, dystonia, ataxia, and spasticity. Severe combined respiratory chain deficiency may be found in severely affected individuals.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
14.8 TPM
Linfócitos
13.3 TPM
Cervix Endocervix
12.3 TPM
Ovário
11.9 TPM
Nervo tibial
11.9 TPM
OUTRAS DOENÇAS (3)
neurodevelopmental disorder, mitochondrial, with abnormal movements and lactic acidosis, with or without seizuresparkinsonism-dystonia 3, childhood-onsetparkinsonism-dystonia, infantile
HGNC:12730UniProt:Q9UGM6
PNKDProbable thioesterase PNKDDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Probable thioesterase that may play a role in cellular detoxification processes; it likely acts on a yet-unknown alpha-hydroxythioester substrate (Probable). In vitro, it is able to catalyze the hydrolysis of S-D-lactoyl-glutathione to form glutathione and D-lactic acid at very low rate, though this reaction is not physiologically relevant in vivo (PubMed:21487022)

LOCALIZAÇÃO

Cell membraneMitochondrionCytoplasmGolgi apparatusEndoplasmic reticulum

VIAS BIOLÓGICAS (1)
Complex IV assembly
MECANISMO DE DOENÇA

Paroxysmal non-kinesigenic dyskinesia 1

An autosomal dominant movement disorder characterized by attacks of dystonia, chorea, and athetosis. The attacks of involuntary movements are brought on by stress, alcohol, fatigue or caffeine, and generally last between a few seconds and four hours or longer. The attacks may begin in one limb and spread throughout the body, including the face.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Fígado
73.9 TPM
Brain Frontal Cortex BA9
70.5 TPM
Próstata
54.4 TPM
Tireoide
54.3 TPM
Córtex cerebral
52.6 TPM
INTERAÇÕES PROTEICAS (4)
OUTRAS DOENÇAS (2)
paroxysmal nonkinesigenic dyskinesia 1paroxysmal nonkinesigenic dyskinesia
HGNC:9153UniProt:Q8N490
TMEM151ATransmembrane protein 151ADisease-causing germline mutation(s) inTolerante
LOCALIZAÇÃO

Endoplasmic reticulum membraneCell projection, axonCell projection, dendrite

MECANISMO DE DOENÇA

Episodic kinesigenic dyskinesia 3

A form of paroxysmal kinesigenic dyskinesia, a neurologic condition characterized by recurrent and brief attacks of abnormal involuntary movements. These attacks can involve dystonic postures, chorea, or athetosis. EKD3 is an autosomal dominant form with incomplete penetrance and onset in late childhood or early adolescence. Symptoms are usually triggered by sudden movement or stress, and resolve in most patients in their early twenties or later.

EXPRESSÃO TECIDUAL(Tecido-específico)
Brain Spinal cord cervical c-1
180.9 TPM
Brain Frontal Cortex BA9
55.3 TPM
Córtex cerebral
55.0 TPM
Hipocampo
54.3 TPM
Substância negra
51.5 TPM
OUTRAS DOENÇAS (1)
episodic kinesigenic dyskinesia 3
HGNC:HGNC:28497UniProt:Q8N4L1
PRKRAInterferon-inducible double-stranded RNA-dependent protein kinase activator ADisease-causing germline mutation(s) inTolerante
FUNÇÃO

Activates EIF2AK2/PKR in the absence of double-stranded RNA (dsRNA), leading to phosphorylation of EIF2S1/EFI2-alpha and inhibition of translation and induction of apoptosis. Required for siRNA production by DICER1 and for subsequent siRNA-mediated post-transcriptional gene silencing. Does not seem to be required for processing of pre-miRNA to miRNA by DICER1. Promotes UBC9-p53/TP53 association and sumoylation and phosphorylation of p53/TP53 at 'Lys-386' at 'Ser-392' respectively and enhances it

LOCALIZAÇÃO

Cytoplasm, perinuclear regionCytoplasm

VIAS BIOLÓGICAS (2)
MicroRNA (miRNA) biogenesisSmall interfering RNA (siRNA) biogenesis
MECANISMO DE DOENÇA

Dystonia 16

An early-onset dystonia-parkinsonism disorder. Dystonia is defined by the presence of sustained involuntary muscle contraction, often leading to abnormal postures. DYT16 patients have progressive, generalized dystonia with axial muscle involvement, oro-mandibular (sardonic smile) and laryngeal dystonia and, in some cases, parkinsonian features.

EXPRESSÃO TECIDUAL(Ubíquo)
Artéria tibial
67.7 TPM
Aorta
59.4 TPM
Músculo esquelético
54.4 TPM
Útero
52.1 TPM
Artéria coronária
50.8 TPM
OUTRAS DOENÇAS (1)
dystonia 16
HGNC:9438UniProt:O75569
SLC6A3Sodium-dependent dopamine transporterDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Mediates sodium- and chloride-dependent transport of dopamine (PubMed:10375632, PubMed:11093780, PubMed:1406597, PubMed:15505207, PubMed:19478460, PubMed:39112701, PubMed:39112703, PubMed:39112705, PubMed:8302271). Also mediates sodium- and chloride-dependent transport of norepinephrine (also known as noradrenaline) (By similarity). Regulator of light-dependent retinal hyaloid vessel regression, downstream of OPN5 signaling (By similarity)

LOCALIZAÇÃO

Cell membraneCell projection, neuron projectionCell projection, axon

VIAS BIOLÓGICAS (2)
Dopamine clearance from the synaptic cleftSLC-mediated transport of neurotransmitters
MECANISMO DE DOENÇA

Parkinsonism-dystonia 1, infantile-onset

An autosomal recessive neurodegenerative disorder characterized by infantile onset of parkinsonism and dystonia. Other neurologic features include global developmental delay, bradykinesia and pyramidal tract signs.

EXPRESSÃO TECIDUAL(Tecido-específico)
Substância negra
34.7 TPM
Tireoide
1.8 TPM
Ovário
1.1 TPM
Cervix Ectocervix
1.1 TPM
Testículo
0.9 TPM
OUTRAS DOENÇAS (3)
classic dopamine transporter deficiency syndromeparkinsonism-dystonia, infantiletobacco addiction, susceptibility to
HGNC:11049UniProt:Q01959
KCTD17BTB/POZ domain-containing protein KCTD17Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Substrate-adapter for CUL3-RING ubiquitin ligase complexes which mediates the ubiquitination and subsequent proteasomal degradation of TCHP, a protein involved in ciliogenesis down-regulation. Thereby, positively regulates ciliogenesis, playing a crucial role in the initial steps of axoneme extension (PubMed:25270598). May also play a role in endoplasmic reticulum calcium ion homeostasis (PubMed:25983243)

LOCALIZAÇÃO

Cytoplasm

MECANISMO DE DOENÇA

Dystonia 26, myoclonic

A form of dystonia, a disorder defined by the presence of sustained involuntary muscle contraction, often leading to abnormal postures. DYT26 is an autosomal dominant, progressive disorder characterized by a combination of non-epileptic myoclonic jerks and dystonia. Affected individuals manifest myoclonic jerks in the upper limbs during the first or second decade of life, and later develop dystonia with predominant involvement of the craniocervical regions and sometimes the trunk and/or lower limbs.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Caudate basal ganglia
112.4 TPM
Brain Putamen basal ganglia
103.4 TPM
Testículo
86.7 TPM
Brain Nucleus accumbens basal ganglia
78.9 TPM
Brain Frontal Cortex BA9
67.5 TPM
OUTRAS DOENÇAS (2)
myoclonic dystonia 26myoclonus-dystonia syndrome
HGNC:25705UniProt:Q8N5Z5
SLC2A1Solute carrier family 2, facilitated glucose transporter member 1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Facilitative glucose transporter, which is responsible for constitutive or basal glucose uptake (PubMed:10227690, PubMed:10954735, PubMed:18245775, PubMed:19449892, PubMed:25982116, PubMed:27078104, PubMed:32860739). Has a very broad substrate specificity; can transport a wide range of aldoses including both pentoses and hexoses (PubMed:18245775, PubMed:19449892). Most important energy carrier of the brain: present at the blood-brain barrier and assures the energy-independent, facilitative trans

LOCALIZAÇÃO

Cell membraneMelanosomePhotoreceptor inner segment

VIAS BIOLÓGICAS (3)
Vitamin C (ascorbate) metabolismCellular hexose transportRegulation of insulin secretion
MECANISMO DE DOENÇA

GLUT1 deficiency syndrome 1

A neurologic disorder showing wide phenotypic variability. The most severe 'classic' phenotype comprises infantile-onset epileptic encephalopathy associated with delayed development, acquired microcephaly, motor incoordination, and spasticity. Onset of seizures, usually characterized by apneic episodes, staring spells, and episodic eye movements, occurs within the first 4 months of life. Other paroxysmal findings include intermittent ataxia, confusion, lethargy, sleep disturbance, and headache. Varying degrees of cognitive impairment can occur, ranging from learning disabilities to severe intellectual disability.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
703.8 TPM
Skin Not Sun Exposed Suprapubic
272.6 TPM
Skin Sun Exposed Lower leg
265.8 TPM
Vagina
176.1 TPM
Esôfago - Mucosa
154.8 TPM
OUTRAS DOENÇAS (8)
childhood onset GLUT1 deficiency syndrome 2hereditary cryohydrocytosis with reduced stomatindystonia 9encephalopathy due to GLUT1 deficiency
HGNC:11005UniProt:P11166
SGCEEpsilon-sarcoglycanDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Component of the sarcoglycan complex, a subcomplex of the dystrophin-glycoprotein complex which forms a link between the F-actin cytoskeleton and the extracellular matrix

LOCALIZAÇÃO

Cell membrane, sarcolemmaCytoplasm, cytoskeletonCell projection, dendriteGolgi apparatus

VIAS BIOLÓGICAS (1)
Formation of the dystrophin-glycoprotein complex (DGC)
MECANISMO DE DOENÇA

Dystonia 11, myoclonic

A myoclonic dystonia. Dystonia is defined by the presence of sustained involuntary muscle contractions, often leading to abnormal postures. DYT11 is characterized by involuntary lightning jerks and dystonic movements and postures alleviated by alcohol. Inheritance is autosomal dominant. The age of onset, pattern of body involvement, presence of myoclonus and response to alcohol are all variable.

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
121.7 TPM
Nervo tibial
89.5 TPM
Aorta
82.0 TPM
Cervix Ectocervix
78.5 TPM
Fallopian Tube
75.7 TPM
OUTRAS DOENÇAS (2)
myoclonic dystonia 11myoclonus-dystonia syndrome
HGNC:10808UniProt:O43556

Medicamentos e terapias

ZONISAMIDEPhase 3

Mecanismo: Sodium channel alpha subunit blocker

Ver mais no OpenTargets

Variantes genéticas (ClinVar)

10,791 variantes patogênicas registradas no ClinVar.

🧬 SLC18A2: NM_003054.6(SLC18A2):c.1307-14C>G ()
🧬 SLC18A2: NM_003054.6(SLC18A2):c.464G>T (p.Arg155Ile) ()
🧬 SLC18A2: NM_003054.6(SLC18A2):c.1184T>C (p.Ile395Thr) ()
🧬 SLC18A2: NM_003054.6(SLC18A2):c.464+2T>C ()
🧬 SLC18A2: NM_003054.6(SLC18A2):c.700+2T>G ()
Ver todas no ClinVar

Vias biológicas (Reactome)

66 vias biológicas associadas aos genes desta condição.

Serotonin Neurotransmitter Release Cycle Norepinephrine Neurotransmitter Release Cycle Dopamine Neurotransmitter Release Cycle DNA Damage/Telomere Stress Induced Senescence Regulation of HSF1-mediated heat shock response Autodegradation of the E3 ubiquitin ligase COP1 HDR through Single Strand Annealing (SSA) HDR through Homologous Recombination (HRR) Sensing of DNA Double Strand Breaks Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks Resolution of D-loop Structures through Holliday Junction Intermediates Nonhomologous End-Joining (NHEJ) Homologous DNA Pairing and Strand Exchange Processing of DNA double-strand break ends Presynaptic phase of homologous DNA pairing and strand exchange TP53 Regulates Transcription of DNA Repair Genes TP53 Regulates Transcription of Genes Involved in Cytochrome C Release TP53 Regulates Transcription of Caspase Activators and Caspases Regulation of TP53 Activity through Phosphorylation Regulation of TP53 Degradation Regulation of TP53 Activity through Methylation G2/M DNA damage checkpoint Stabilization of p53 Meiotic recombination Pexophagy Defective homologous recombination repair (HRR) due to BRCA1 loss of function Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function Impaired BRCA2 binding to RAD51 Impaired BRCA2 binding to PALB2 Presynaptic depolarization and calcium channel opening Regulation of insulin secretion Activation of G protein gated Potassium channels Potassium transport channels Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits Voltage gated Potassium channels Dopamine receptors Cargo recognition for clathrin-mediated endocytosis SLIT2 gene expression is stimulated by ISL1 Primary multipotent pancreatic progenitor cell produces trunk bipotent pancreatic progenitor cell HIV Transcription Initiation RNA Polymerase II HIV Promoter Escape Transcription of the HIV genome RNA Polymerase II Pre-transcription Events RNA Polymerase II Promoter Escape RNA Polymerase II Transcription Pre-Initiation And Promoter Opening RNA Polymerase II Transcription Initiation RNA Polymerase II Transcription Initiation And Promoter Clearance Ion homeostasis Ion transport by P-type ATPases Potential therapeutics for SARS Mitochondrial tRNA aminoacylation Complex IV assembly MicroRNA (miRNA) biogenesis Small interfering RNA (siRNA) biogenesis PKR-mediated signaling Dopamine clearance from the synaptic cleft SLC-mediated transport of neurotransmitters Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS) Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS) Cellular hexose transport Vitamin C (ascorbate) metabolism Defective SLC2A1 causes GLUT1 deficiency syndrome 1 (GLUT1DS1) Lactose synthesis Formation of the dystrophin-glycoprotein complex (DGC)

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
3Fase 31
·Pré-clínico1
Medicamentos catalogadosEnsaios clínicos· 1 medicamento · 1 ensaio
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Síndrome distonia-plus

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Pesquisa e ensaios clínicos

1 ensaios clínicos encontrados, 1 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
49 papers (10 anos)
#1

Fibroblast Transcriptomics in Molecular Diagnostics of a Comprehensive Dystonia Cohort.

Annals of neurology2026 Feb 02

Genomic sequencing leaves >50% of dystonia-affected individuals without a diagnosis. Where DNA-oriented approaches remain insufficient, integrating multiomics is essential to advance genome interpretation. Herein, we incorporated RNA sequencing (RNA-seq) data from 167 patients with dystonia across a range of ages and presentations. We leveraged an RNA-seq analysis pipeline, focused on the identification of expression and splicing aberrations, on RNA-seq from skin biopsies. The recruited patients had early-onset dystonia in 85.0%, non-focal dystonia in 92.2%, and coexisting features in 76.0%. Thirty-six patient samples with pre-identified variants (36/167, 21.6%) and 131 samples with no previously prioritized diagnostic candidates from genomic sequencing (131/167, 78.4%) were evaluated. We found that >80% of dystonia-associated genes were detected by fibroblast RNA-seq. Expression and splicing aberration analyses produced a manageable number of significant RNA defects affecting dystonia-associated genes. The approach was especially successful in validating pathogenic effects of loss-of-function variants, with disease-relevant RNA-underexpression detected for 66.7% (10/15). Studying aberrant expression and splicing in the context of other pre-identified variant types yielded relevant results in 28.6% (6/21 samples). We obtained a 6.9% (9/131) diagnostic uplift for patients without prior candidates, all of whom exhibited combined dystonia with autosomal recessive inheritance. The new diagnoses from RNA-seq and genomic reanalysis were based on previously neglected splice-region (3/9) and deep(er) intronic (6/9) variants. For the observed events, integration of new machine-learning scores predicted corresponding aberrant gene expression in the brain. Fibroblast-based RNA-seq in our selected cohort improved variant interpretation and offered a modest yield in patients without prior candidate variants. ANN NEUROL 2026.

#2

A Twisting Diagnosis: A New Case of VPS16-Related Hyperkinetic Spectrum and Literature Review.

Movement disorders clinical practice2026 Jan
#3

Phenotypic comparison between combined dystonia-parkinsonism and idiopathic adult-onset dystonia.

Journal of neural transmission (Vienna, Austria : 1996)2025 Jun

The clinical characteristics of dystonia occurring in association with sporadic neurodegenerative parkinsonism have not been systematically explored or compared with those of idiopathic adult-onset dystonia. This study aims to compare demographic and clinical features, including the distribution of dystonia at onset, dystonia-associated features, and the propensity for spread between patients with combined dystonia-parkinsonism and those with idiopathic adult-onset dystonia. Patients were selected from the Italian Dystonia Registry. The study cohort included 130 patients with combined dystonia-parkinsonism and 355 age- and sex-matched patients with isolated adult-onset idiopathic dystonia. The comparison between combined dystonia-parkinsonism and idiopathic dystonia revealed differences in the distribution of dystonia across body regions, with non-task-specific upper limb dystonia, lower limb dystonia, and trunk dystonia occurring more frequently in patients with combined dystonia-parkinsonism. Additionally, this group exhibited a lower frequency of head tremor, eye symptoms associated with blepharospasm, and sensory tricks, alongside a comparable frequency of neck pain related to cervical dystonia and a family history of dystonia or tremor. The clinical presentation of dystonia differs between combined dystonia-parkinsonism and idiopathic dystonia, especially in terms of the body regions affected. These differences underscore the necessity for additional research and suggest underlying pathophysiological disparities between etiological categories that could significantly influence future diagnostics and therapeutic approaches.

#4

Causative Role of the SLC6A1 p.Asp451Gly Variant in a Patient with Combined Dystonia and Neurodevelopmental Disorder.

Movement disorders clinical practice2025 Feb
#5

Genetic analysis of IRF2BPL in a Taiwanese dystonia cohort: The genotype and phenotype correlation.

Annals of clinical and translational neurology2024 Jun

IRF2BPL mutation has been associated with a rare neurodevelopmental disorder with abnormal movements, including dystonia. However, the role of IRF2BPL in dystonia remains elusive. We aimed to investigate IRF2BPL mutations in a Taiwanese dystonia cohort. A total of 300 unrelated patients with molecularly unassigned isolated (n = 256) or combined dystonia (n = 44) were enrolled between January 2015 and July 2023. The IRF2BPL variants were analyzed based on whole exome sequencing. The in silico prediction of the identified potential pathogenic variant was performed to predict its pathogenicity. We also compared the clinical and genetic features to previous literature reports. We identified one adolescent patient carrying a de novo heterozygous pathogenic variant of IRF2BPL, c.379C>T (p.Gln127Ter), who presented with generalized dystonia, developmental regression, and epilepsy (0.33% of our dystonia cohort). This variant resides within the polyglutamine (poly Q) domain before the first PEST sequence block of the IRF2BPL protein, remarkably truncating the protein structure. Combined with other patients with IRF2BPL mutations in the literature (n = 60), patients with variants in the poly Q domain have a higher rate of nonsense mutations (p < 0.001) and epilepsy (p = 0.008) than patients with variants in other domains. Furthermore, as our index patient, carriers with substitutions before the first PEST sequence block have significantly older age of onset (p < 0.01) and higher non-epilepsy symptoms, including generalized dystonia (p = 0.003), and ataxia (p = 0.003). IRF2BPL mutation is a rare cause of dystonia in our population. Mutations in different domains of IRF2BPL exhibit different phenotypes.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC15 artigos no totalmostrando 46

2026

Fibroblast Transcriptomics in Molecular Diagnostics of a Comprehensive Dystonia Cohort.

Annals of neurology
2026

A Twisting Diagnosis: A New Case of VPS16-Related Hyperkinetic Spectrum and Literature Review.

Movement disorders clinical practice
2025

Phenotypic comparison between combined dystonia-parkinsonism and idiopathic adult-onset dystonia.

Journal of neural transmission (Vienna, Austria : 1996)
2024

Decoding Dystonia in Autoimmune Disorders: A Scoping Review.

Tremor and other hyperkinetic movements (New York, N.Y.)
2025

Causative Role of the SLC6A1 p.Asp451Gly Variant in a Patient with Combined Dystonia and Neurodevelopmental Disorder.

Movement disorders clinical practice
2024

Adult-onset YY1-associated combined dystonia syndrome with infantile nystagmus as a diagnostic clue.

Parkinsonism &amp; related disorders
2024

Genetic analysis of IRF2BPL in a Taiwanese dystonia cohort: The genotype and phenotype correlation.

Annals of clinical and translational neurology
2024

The Clinical Spectrum of ANO3-Report of a New Family and Literature Review.

Movement disorders clinical practice
2024

Large-Scale Screening: Phenotypic and Mutational Spectrum in Isolated and Combined Dystonia Genes.

Movement disorders : official journal of the Movement Disorder Society
2023

Deep Brain Stimulation for Dystonia: Experience of a Moroccan University Hospital.

Pediatric neurology
2023

Isolated and combined dystonias: Update.

Handbook of clinical neurology
2023

Blood neurofilament light chain as a surrogate marker for dystonia.

European journal of neurology
2023

Genetic analysis of IMPDH2 gene in Taiwanese patients with isolated or combined dystonia.

Parkinsonism &amp; related disorders
2022

ACTB gene mutation in combined Dystonia-Deafness syndrome with parkinsonism: Expanding the phenotype and highlighting the long-term GPi DBS outcome.

Parkinsonism &amp; related disorders
2022

TANGO2 Mutation: A Genetic Cause of Multifocal Combined Dystonia.

Movement disorders clinical practice
2022

Oromandibular Dystonia - A Systematic Review.

Annals of Indian Academy of Neurology
2022

Possible EIF2AK2-Associated Stress-Related Neurological Decompensation with Combined Dystonia and Striatal Lesions.

Movement disorders clinical practice
2022

A Clinical and Integrated Genetic Study of Isolated and Combined Dystonia in Taiwan.

The Journal of molecular diagnostics : JMD
2021

Predicting Outcome in a Cohort of Isolated and Combined Dystonia within Probabilistic Brain Mapping.

Movement disorders clinical practice
2021

Understanding Psychiatric Disorders in Idiopathic and Inherited (Monogenic) Forms of Isolated and Combined Dystonia: A Systematic Review.

The Journal of neuropsychiatry and clinical neurosciences
2021

Tremor in Primary Monogenic Dystonia.

Current neurology and neuroscience reports
2021

Brain Regional Differences in Hexanucleotide Repeat Length in X-Linked Dystonia-Parkinsonism Using Nanopore Sequencing.

Neurology. Genetics
2020

Functional Dystonia: Differentiation From Primary Dystonia and Multidisciplinary Treatments.

Frontiers in neurology
2021

Clinically relevant copy-number variants in exome sequencing data of patients with dystonia.

Parkinsonism &amp; related disorders
2021

Genetic Dystonias: Update on Classification and New Genetic Discoveries.

Current neurology and neuroscience reports
2021

The expanding clinical and genetic spectrum of ANO3 dystonia.

Neuroscience letters
2020

Little Brain, Big Expectations.

Brain sciences
2021

Combined dystonias: clinical and genetic updates.

Journal of neural transmission (Vienna, Austria : 1996)
2020

Monogenic variants in dystonia: an exome-wide sequencing study.

The Lancet. Neurology
2020

Loss-of-Function Mutations in NR4A2 Cause Dopa-Responsive Dystonia Parkinsonism.

Movement disorders : official journal of the Movement Disorder Society
2019

Pharyngeal Dystonia Misdiagnosed as Cricopharyngeal Dysphagia Successfully Treated by Pharmacotherapy.

Annals of rehabilitation medicine
2019

Whole genome sequencing for the genetic diagnosis of heterogenous dystonia phenotypes.

Parkinsonism &amp; related disorders
2020

Clinical diagnostic exome sequencing in dystonia: Genetic testing challenges for complex conditions.

Clinical genetics
2019

Mitochondrial complex I NUBPL mutations cause combined dystonia with bilateral striatal necrosis and cerebellar atrophy.

European journal of neurology
2019

Combined Dystonia With Self-Mutilation in 6-Pyruvoyl-Tetrahydropterin Synthase (PTPS) Deficiency: A Case Report.

Movement disorders clinical practice
2018

Pediatric Deep Brain Stimulation Using Awake Recording and Stimulation for Target Selection in an Inpatient Neuromodulation Monitoring Unit.

Brain sciences
2018

Phenotype variability and allelic heterogeneity in KMT2B-Associated disease.

Parkinsonism &amp; related disorders
2017

Molecular diversity of combined and complex dystonia: insights from diagnostic exome sequencing.

Neurogenetics
2017

Deep Brain Stimulation for the Dystonias: Evidence, Knowledge Gaps, and Practical Considerations.

Movement disorders clinical practice
2017

Relationship of Cognitive Function to Motor Symptoms and Mood Disorders in Patients With Isolated Dystonia.

Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology
2017

Clinical exome sequencing in early-onset generalized dystonia and large-scale resequencing follow-up.

Movement disorders : official journal of the Movement Disorder Society
2016

Diagnosis and Management of Dystonia.

Continuum (Minneapolis, Minn.)
2016

The role of mutations in COL6A3 in isolated dystonia.

Journal of neurology
2015

First Report of a Filipino with Mohr-Tranebjaerg Syndrome.

Movement disorders clinical practice
2015

Phenotype of non-c.907_909delGAG mutations in TOR1A: DYT1 dystonia revisited.

Parkinsonism &amp; related disorders
2015

Isolated and combined dystonia syndromes - an update on new genes and their phenotypes.

European journal of neurology

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Síndrome distonia-plus.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Síndrome distonia-plus

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Fibroblast Transcriptomics in Molecular Diagnostics of a Comprehensive Dystonia Cohort.
    Annals of neurology· 2026· PMID 41623120mais citado
  2. A Twisting Diagnosis: A New Case of VPS16-Related Hyperkinetic Spectrum and Literature Review.
    Movement disorders clinical practice· 2026· PMID 40827393mais citado
  3. Phenotypic comparison between combined dystonia-parkinsonism and idiopathic adult-onset dystonia.
    Journal of neural transmission (Vienna, Austria : 1996)· 2025· PMID 40246732mais citado
  4. Causative Role of the SLC6A1 p.Asp451Gly Variant in a Patient with Combined Dystonia and Neurodevelopmental Disorder.
    Movement disorders clinical practice· 2025· PMID 39446029mais citado
  5. Genetic analysis of IRF2BPL in a Taiwanese dystonia cohort: The genotype and phenotype correlation.
    Annals of clinical and translational neurology· 2024· PMID 38650104mais citado
  6. CACNA1C-Related Channelopathy Presenting With Adult-Onset Combined Dystonia-Parkinsonism: A Novel Neurological Presentation.
    Am J Med Genet A· 2026· PMID 41978253recente
  7. Decoding Dystonia in Autoimmune Disorders: A Scoping Review.
    Tremor Other Hyperkinet Mov (N Y)· 2024· PMID 39651491recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:98203(Orphanet)
  2. MONDO:0020065(MONDO)
  3. Distonia e Espasticidade(PCDT · Ministério da Saúde)
  4. GARD:19432(GARD (NIH))
  5. Variantes catalogadas(ClinVar)
  6. Busca completa no PubMed(PubMed)
  7. Q55789097(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Síndrome distonia-plus
Compêndio · Raras BR

Síndrome distonia-plus

ORPHA:98203 · MONDO:0020065
🇧🇷 Brasil SUS
Geral
Ensaios
1 ativos
Medicamentos
1 registrados
MedGen
UMLS
C5680244
Repurposing
1 candidato
procyclidineacetylcholine receptor antagonist
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades